Zura Bio Ltd (ZURA)
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Zura Bio Limited
- tibulizumabREADOUTCash runway at this date: 2yr
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Active, not recruiting
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Tibulizumab
Systemic Sclerosis (SSc), Scleroderma
NCT06843239Enrollment80StartFeb 2025Primary CompletionMay 2027est.CompletionJan 2028est. - Phase 2Active, not recruiting
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Tibulizumab Dose A, Tibulizumab Dose B
Hidradenitis Suppurativa (HS)
NCT06993610Enrollment247StartMay 2025Primary CompletionSep 2026CompletionApr 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Active, not recruiting | Tibulizumab | NCT06843239 |
| Phase 2 | Active, not recruiting | Tibulizumab Dose A, Tibulizumab Dose B | NCT06993610 |